Value
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.7 |
| P/S | 8.6 |
| EV/EBITDA | 6.6 |
| Fwd P/E | 9.2 |
| PEG | 9.8 |
| Analyst target | 4.0 |
- ▸Forward P/E: 10.5x
- ▸PEG: 0.54
- ▸Attractively valued
PRI · Why this verdict
Why Primerica (PRI) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.4/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Primerica is a high-quality life insurance and financial products compounder with 33% ROE, 23% margins and a 4-of-4 earnings beat streak, but the price is within 2.6% of the analyst target so the setup suggests waiting for a pullback.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Primerica relies on reinsurance for 90% of mortality risk and on a very limited number of mortgage lenders, creating counterparty concentration. Bear case | Reinsurance arrangements and lender relationships stay in place without worse terms over the next 12 months. | →Stable |
| CounterThe failure or repricing of a main reinsurer could suddenly raise capital needs and cut earnings given how much risk is ceded. | ||
Primerica earns an excellent 33% ROE with 23% margins and 130% free cash flow conversion of net income, backed by a wide economic moat. Quality breakdown | ROE stays above 25% and free cash flow stays at or above 100% of net income over 12 months. | →Stable |
| CounterPeer-relative growth is middling and the high ROE depends on a favorable reinsurance structure that may not hold. | ||
Primerica has beaten EPS estimates in 4 straight quarters with an average surprise of 9.6%, most recently $6.41 versus $6.01 expected. Catalyst breakdown | EPS keeps beating estimates in the November 2026 report and later quarters. | ↑Improving |
| CounterEarnings in 11 days may already be priced in, and a stock below its 200-day average could fall even on a modest beat. | ||
The stock trades at a forward P/E of 10.1x with a PEG of 0.52 and a dividend aristocrat yield of 1.8%. Valuation breakdown | Earnings growth holds the forward P/E at or below 11x while the dividend continues to rise. | ↓Deteriorating |
| CounterValue rank versus peers is weak at about 3.2/10, so the stock is cheap against its own history more than against competitors. | ||
The $274.43 price is 2.6% below the $281.59 analyst target, leaving reward-to-risk of only 0.52 against 5.0% downside to the stop. Upside pct | Earnings growth lifts the analyst target above $300, restoring upside above 10%. | ↓Deteriorating |
| CounterLimited upside combined with the price already below its 200-day average argues for waiting for a pullback toward the $260.71 entry. | ||
Primerica relies on reinsurance for 90% of mortality risk and on a very limited number of mortgage lenders, creating counterparty concentration.
→StableBear case
- Expectation
- Reinsurance arrangements and lender relationships stay in place without worse terms over the next 12 months.
CounterThe failure or repricing of a main reinsurer could suddenly raise capital needs and cut earnings given how much risk is ceded.
Primerica earns an excellent 33% ROE with 23% margins and 130% free cash flow conversion of net income, backed by a wide economic moat.
→StableQuality breakdown
- Expectation
- ROE stays above 25% and free cash flow stays at or above 100% of net income over 12 months.
CounterPeer-relative growth is middling and the high ROE depends on a favorable reinsurance structure that may not hold.
Primerica has beaten EPS estimates in 4 straight quarters with an average surprise of 9.6%, most recently $6.41 versus $6.01 expected.
↑ImprovingCatalyst breakdown
- Expectation
- EPS keeps beating estimates in the November 2026 report and later quarters.
CounterEarnings in 11 days may already be priced in, and a stock below its 200-day average could fall even on a modest beat.
The stock trades at a forward P/E of 10.1x with a PEG of 0.52 and a dividend aristocrat yield of 1.8%.
↓DeterioratingValuation breakdown
- Expectation
- Earnings growth holds the forward P/E at or below 11x while the dividend continues to rise.
CounterValue rank versus peers is weak at about 3.2/10, so the stock is cheap against its own history more than against competitors.
The $274.43 price is 2.6% below the $281.59 analyst target, leaving reward-to-risk of only 0.52 against 5.0% downside to the stop.
↓DeterioratingUpside pct
- Expectation
- Earnings growth lifts the analyst target above $300, restoring upside above 10%.
CounterLimited upside combined with the price already below its 200-day average argues for waiting for a pullback toward the $260.71 entry.
Per-dimension breakdown
Quality
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 3.1 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.3 |
| FCF quality | 9.3 |
| Moat | 7.6 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 33%
- ▸Strong margins: 23%
- ▸Excellent cash conversion: 130% FCF/NI
- ▸Wide economic moat
Growth
5.3/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.7 |
| EPS growth | 5.9 |
Momentum
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 5.0 |
| Price target | 6.7 |
Insider
4.7/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 4.4 |
- ▸Insider selling (low materiality) — $1,130,572 (0.013% of mkt cap)
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.2 |
| quality rank | 8.7 |
| growth rank | 4.7 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 3.4 |
| 52w position | 7.8 |
| gap | 5.0 |
Risk (lower is worse)
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 3.7 |
| volatility | 6.9 |
| implied vol | 6.3 |
| beta | 8.0 |
| debt equity | 6.7 |
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 7.2 |
| dividend safety | 8.5 |
| news activity | 7.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend aristocrat: 1.7% yield
How the verdict was assembled
Engine trigger
Downgraded from BUY WAIT — price $289.51 vs the analyst target $281.59: -2.7% upside; No upside left.
Engine technical detail
verdict_path:
L4:PATH_D_BALANCED|V8:TARGET_REACHED|SANITY:BUY+upside<=0Passed (6)
- MOMENTUM:6.9>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.48
Upside
-2.7%
Downside
5.6%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 58, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The D-path balanced-high-score trigger fired: quality 8.5 and momentum 6.9 both cleared their gates at R:R of -0.48.
The strongest dimensions are Quality at 8.5, Value at 7.8, and Catalyst at 7.5; the weakest are Technical at 4.0, Insider at 4.7, and Peer rank at 5.1. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.48 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Excellent Returns And Margins
Trip ifROE falls below 22% from the current 33%.
- P2Consistent Earnings Beat Streak
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Attractive Valuation And Dividend
Trip ifForward P/E rises above 14x from the current 10.1x.
- P4Price Near Analyst Target
Trip ifPrice falls below the $250.05 stop level.
- P5Reinsurance Counterparty Concentration
Trip ifReinsured share of mortality risk falls below 70% or a reinsurer downgrade exceeds 2 rating notches.